Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 132

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 132
---
 its name to “CERo Therapeutics Holdings, Inc.” The unaudited pro forma condensed combined financial information has been prepared using the assumptions below: On June 4, 2023, Legacy CERo entered into a bridge financing agreement (the “Bridge Financing”) in anticipation of Legacy CERo completing the Business Combination with PBAX pursuant to a definitive Business Combination Agreement. On June 6, 2023, Legacy CERo sold the Convertible Bridge Notes with an aggregate principal amount of $605,230 to certain eligible participants. The Convertible Bridge Notes were automatically converted (principal and accrued interest) upon the Business Combination into an aggregate of 628 shares of Series A Preferred Stock at conversion rate of $1,000 per share, and all of the Convertible Bridge Notes were retired. An additional 1,000,000 shares of restricted Common Stock were issued to select Legacy CERo stockholders and Convertible Bridge Note investors and a corresponding 1,000,000 shares of Common Stock held by the Sponsor have been restricted. Upon the filing of an investigational new drug (“IND”) application with the FDA, the restrictions upon the shares of Common Stock issued to such Legacy CERo stockholders and Convertible Bridge Note investors will be removed, and the shares of Common Stock held by the Sponsor will be retired. Should CERo fail to file an IND with the FDA, the shares of Common Stock issued to such Legacy CERo stockholders and Convertible Bridge Note investors will be retired and the restrictions on the Sponsor’s Common Stock will be removed. Of the 2,000,000 shares of Common Stock held by Sponsor, 250,000 shares were transferred to a key investor, 875,000 shares were distributed to select Legacy CERo stockholders and Convertible Bridge Note investors as earnout shares, and 875,000 shares being retained by the Sponsor. CERo also issued 1,943,550 new shares of Common Stock in connection with the Business Combination, consisting of (i) 1,649,500 shares issued to select vendors in lieu of cash payment for services provided related to the Business Combination, (ii) 175,000 shares provided to individuals as compensation and (iii) 119,050 shares issued to Keystone as consideration for its entry into the Keystone Equity Financing. Additionally, in February 2024, CERo consummated a private placement of 10,039 shares of Series A Preferred Stock, warrants to purchase 612,746